09860 艾迪康控股
ADICON HOLDINGS
ADICON HOLDINGS
| Listing Date | 2023/06/30 |
| Listing Price | 12.320 |
Quote
Subscription Result
- Subscription Rate1.06x
- Guarantee One Lot Size1 lot
- One Lot Success Rate100%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
ADICON Holdings is one of the top three independent clinical laboratory, or ICL, service providers in China in terms of total revenues. It offers comprehensive and best-in-class testing services primarily to hospitals and health check centers through an integrated network of 33 self-operated laboratories across China.
--
As of December 31, 2022, 18 of laboratories were accredited by ISO1518. Its testing portfolio consists of over 4,000 medical diagnostic tests, including over 1,700 routine tests and over 2,300 esoteric tests.
--
The Group operates a dedicated cold-chain logistics network covering more than 19,000 customers across 30 provinces and municipalities and over 1,600 cities and counties in China by the end of 2022. It also assembled a dedicated sales and marketing team of over 1,500 personnel.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 500 |
GLOBAL OFFERING
| No. of Offer Shares | 33.19M shares |
| No. of International Offer Shares | 29.87M shares |
| No. of HK Offer Shares | 3.32M shares |
| Offer Price | $12.32 |
| Stock Code | 9860 |
| Sponsor(s) | Morgan Stanley Asia Limited, Jefferies Hong Kong Limited |
| Underwriter(s) | Morgan Stanley Asia Limited, Jefferies Hong Kong Limited, CLSA Limited, Deutsche Bank AG, Hong Kong Branch, Haitong International Securities Company Limited, The Hongkong and Shanghai Banking Corporation Limited, CCB International Capital Limited, Futu Securities International (Hong Kong) Limited, Huatai Financial Holdings (Hong Kong) Limited, ICBC International Securities Limited, Tiger Brokers (HK) Global Limited, Valuable Capital Limited |
TIME TABLE
| Application Period | Jun 19 (Mon) - noon, Jun 23 (Fri) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Jun 29 (Thu) |
| Result Announcement Date | On or before Jun 29 (Thu) |
| Result Announcement Date | On or before Jun 29 (Thu) |
| Dealings in Shares commence on | Jun 30, 2023. (Fri) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $12.32 |
| Capitalization | 8.91B |
| NAV / share ($) | $1.54 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 12.32, the net proceeds raised would be HKD 83.90M, of which |
| 15% : Strengthening routine and esoteric testing capabilities |
| 25% : Network expansion through establishing new laboratories, partnership investments and development of new channels |
| 25% : Business development activities bringing in both new technologies as well as strategic and bolt-on acquisitions; |
| 15% : Upgrade and expansion of existing laboratories |
| 10% : Investment in operating infrastructure |
| 10% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).